Innovation in Menstrual Pain Management:
A Systematic Review of 3D-Printed Personalized Patches for Dysmenorrhea
Kiran R. Deotale, Nilakshi N. Dhoble*, Nitin N. Padole, Pankaj R. Dhapke, Jagdish R. Baheti
Kamla Nehru College of Pharmacy, Butibori, Nagpur, Maharashtra, India.
*Corresponding Author E-mail: Kirandeotale650@gmail.com, dhoblenn18@gmail.com, nitinpadole27doc@gmail.com, pankajdhpk4@gmail.com, jbaheti@gmail.com
Abstract:
This article discusses the potential of 3D printed, patient-tailored transdermal patches in the treatment of dysmenorrhea. Dysmenorrhea occurs in 45% - 95% of individuals of reproductive age and is often inadequately recognized and sub optimally treated. The article consolidates mechanisms of the disease, clinical presentation and available therapeutic options, highlighting their shortfalls. It is followed by a section presenting 3D printing applications in pharmaceutical sciences and focuses on the part played by these in the field of personalized drug delivery. Different Additive Manufacturing strategies (filament deposition, resin injection, powder sintering machine and powder fusion process) are compared in terms of opportunities and threats: Fused Deposition Modeling (FDM), Stereolithography (SLA), Selective Laser Sintering (SLS) and Direct Energy Deposition (DED). Formulation, material selection and analytical aspect for 3D printed patch are discussed. Advantages of these patches are a personalized fitting, possibility for complex geometries, and precise control over dose and release-kinetics. Applications go beyond menstrual pain to vaccine delivery and personalized medicine. The review also contrasts 3D-printed patches with therapeutic options such as heat therapy, herbal agents and systemic medications along with the limitations that accompany them. Obstacles to adoption —costly equipment and materials, regulatory uncertainty, challenges scaling production — are recognized. Future prospects are with the use of biosensors, AI-driven personalization and 4D printing for responsive release. The conclusion emphasizes the disruptive potential of 3D-printed patches in clinical applications and advocates for additional research, development and regulations to bridge this platform technology from bench-to-bedside for better patient outcomes.
KEYWORDS: Dysmenorrhea, 3D printing, Personalized medicine, Transdermal patch, Menstrual pain.
INTRODUCTION:
Overview of Dysmenorrhea:
Dysmenorrhea is the most common gynecological condition in women of reproductive age around the world, irrespective of ethnicity, age and social class. Prevalence rates vary around the world from 45% to 95% in reproductive-age women, and from 2% to 29% of the participants have indicated they have severe pain. Dysmenorrhea was defined as uterine cramping that is painful in combination with menstrual bleeding. It frequently remains underdiagnosed and undertreated, being classified as primary or secondary according to the numerous etiologiesą. Dysmenorrhea in turn is classified into Primary Dysmenorrhea and Secondary Dysmenorrhea.
Primary Dysmenorrhea:
Primary dysmenorrhea indicates menstrual cramping in the absence of pelvic pathology, usually starting before or with the onset of menses. It often develops after ovulatory cycles are established in adolescence or 6–24 months after menarche2.
Secondary dysmenorrhea:
Secondary dysmenorrhea is menstrual pain that results from an identifiable organic cause. The etiologies may be gynaecological or non-gynaecological. It commonly originates from endometriosis, myometrial diseases like adenomyosis and fibromyomas, post-operative adhesions after gynecological surgery, pelvic inflammatory diseases and ovarian cysts3.
Pathophysiology of dysmenorrhea:
Role of Prostaglandin: Prostaglandins are produced by the action of arachidonic acid cascade through the influence of cyclooxygenases. Lysosomal enzyme PHOSPHOLIPASE A2 controls progesterone availability to affects arachidonic acid synthesis. Progesterone levels reach a peak in the mid-luteal phase after ovulation. In the absence of fertilization, corpus luteum regresses and circulating progesterone declines. This rapid fall of progesterone is linked to the mechanism of recycling and liberation, in a sharp manner4.
Uterine hypercontractility: Increased synthesis of uterine prostaglandins causes increased myometrial contractions leading to ischemia and hypoxia of the uterine musculature resulting in pain5.
Vasopressin: Arginine vasopressin has action on V1a receptors in the myometrium, increasing contraction frequency and amplitude, and enhancing prostaglandin synthesis. This creates hypertonicity of the uterus and ischemic pain6.
Signs of dysmenorrhea: Breast tenderness, Sensation of weight in the lower abdominal area, Backache, Swelling and the legs and anxiety7. Dyspareunia, Menorrhagia, Intermenstrual bleeding, Postcoital bleeding8.
Etiology of dysmenorrhea: Endometriosis, Adenomyosis, Ovarian cysts, Pelvic adhesion, Cervical stenosis9
Treatments and Limitations:
Pharmacotherapy: Current pharmacologic management of dysmenorrhea comprising NSAIDs, combined oral contraceptives, simple analgesics, GnRH agonists/antagonists and progestins. NSAIDs alleviate pain and inflammation, however they are not effective in all patients and can lead to gastrointestinal complications. Oral contraception reduces ovulation and supports the endometrium, but is associated with side effects and contraindications. Symptomatic treatment with pain killers (analgesics) is available since no treatment could halt the progression of disease. GnRH modulators cause hypoestrogenism and its associated menopausal syndrome and loss of bone. Progestins act to inhibit ovulation and reduce estrogen stimulated lesion growth, but may induce mood alteration and irregular bleeding. Each option is suboptimal in effectiveness, tolerability and/or long-term use potential, and there are clear unmet treatment needs10–14.
Non-medication therapies: Other therapies may be considered such as acupunctures, yoga, application of warmth or lifestyle changes. Acupuncture can reduce pain and improve quality of life, with mixed findings and multiple applications needed. Lifestyle changes are not well-supported and may be challenging to adhere to, yet may complement other management. Yoga, which incorporates poses, breathing and meditation to increase flexibility and reduce stress, also can help but certain postures might be difficult for those in acute pain. Thermal therapy is a low-cost and fast-acting treatment; however, it offers only short-term relief and has not been thoroughly assessed in endometriosis. Non-pharmacologic treatments Other than medication, non-pharmacological approaches are plagued by poor adherence, methodological limitations in trials and variable success15–20.
3D Printing Technologies in Pharmaceuticals:
Introduction to 3D printing:
Additive manufacturing (AM) or 3D printing has progressed substantially from the 1980s as a rapid-prototyping method to a viable means for production of final parts in numerous industries. Progress in materials, hardware and software is driving the spread of AM from traditional to new areas such as aerospace, automobile, medical and fashion21,22. 3D printing serves for the opportunity of high-level personalization, waste minimization and the possibility to create complex geometries which are not achievable by conventional manufacturing23. AM produces objects by building them up in layers, using a digital model of the object that can be generated with computer-aided design (CAD) software or captured from 3D scan data. This can provide high-accuracy manufacturing with lower energy usage than some of the existing mass-manufacturing technologies24. The increasing utilization of AM is from shifting the norms for global manufacturing terms: The increase in system efficiency, quality, and productivity makes it serviceable companies are including these technologies in their processes25. Contrary to conventional techniques that need molds or tooling, 3D printing technology translates digital models into complex 3D parts with only a little waste of materials26. Now, more than 50 different 3D printing technologies are available to cater material utilization, speed and precision co-relation27. Being a strong advocate of advanced manufacturing, the 3D printing technique increasingly advances28 making it possible to directly print complicated and functional soft systems with various polymer properties29.
The application of 3D printing in customized drug delivery systems: From personalized diagnosis to implants:
Personalizes drug products that are tailored to the specific needs of individual patients, and 3D printing presents a great potential for advancing personalized medicine. Although from the technology, dosage forms with different dose strength, shape and release properties can be produced, but the real personalization means therapy that has been adapted to patient individualized attributes30.
1. Tailored dosage forms: 3D printing can be used to fabricate personalized tablets combining more than one API or custom dosing such as polypills for elderly patients to improve compliance and pill burden31.
2. Formulations: The availability of 3D printing technology has allowed to produce fast-dissolving orodispersible films for patients who are unable to swallow32.
3. Drug release modulation: 3D printing allows the fabrication of non-conventional shapes and multi-material systems to modulate drug release kinetics or include multiple compartments in a single entity33.
4. Overcoming Low Bioavailability: 3D printing enables the generation of the amorphous form of poorly soluble drugs when combined with strategies such as forming nanocrystals or lipid-based carriers34,35.
Methods of 3D printing:
1. FDM-Fused Deposition Modelling: Fused deposition modeling, also known as fused filament fabrication, is an extrusion-based AM scheme. A filament feedstock is melted by a print head and extruded in a path based on the programmed path. When speed and flow are kept constant, the section of the deposited filament should remain the same as shown in Figure 1. Thin layers are created as molten extruded material bonds with previous layer to build the printed object36.
Figure 1: Fused Deposition Modelling
Advantages:
a. Cost and Accessibility: FDM is often cheaper and more accessible than most of rapid prototyping technologies, the required equipment being less in cost and maintenance.
b. Material Variety and Simplicity: With wide variety of material feedstock choice, as well as a simple material change-out process, FDM lends itself to a range of applications.
c. Efficiency: The FDM production is fairly quick with minimum operating costs compared to some other available techniques.
d. Design Freedom: It is capable of manufacturing complex geometries and components which are difficult to manufacture by conventional process.
Disadvantages:
a. Poor Appearance: There are visible layers or a “stair-step” in the final surface finish, which appears less than ideal.
b. Structural and Mechanical Drawbacks: FDM parts may exhibit anisotropic mechanical properties lower strength in the Z-direction, and experience delamination or warping as a result of thermal stresses.
c. Support Structures: Additional post-processing is needed to remove the sacrificial supports for overhangs.
d. Printing Constraints: Exact 3D printing of complex geometries can be a challenge and build times may be long37.
2. SLA- Stereo-lithography:
Stereolithography (SLA) 3D prints objects by curing liquid resin in a vat using concentrated light. Selective polymerization of resin occurs in all three dimensions by writing the laser at particular depths and filling adjacent areas of the layer up to a specific thickness as shown in Figure 238.
Figure 2. SLA- Stereo-lithography
Advantages:
a. Quality, precision, accuracy: In terms of the quality and resolution, SLA technology provides the smoothest surfaces, finest detail and highest resolution compared with known 3D printing processes making it very adaptable39.
b. Speed and low cost: SLA is suitable for fast turnaround, fine prototype print that can get a model at the low-cost price, which is good for device design and validation.
c. Drug inclusion: SLA permits drugs to be mixed with photopolymers before curing, trapping the drug within the solid matrix.
d. Material diversity: It is possible to use a wide range of materials with SLA, from polymers through ceramics and even some resins suitable for metals40.
Disadvantages:
a. Material limitations: SLA is restricted to UV-curable materials, restricting material options.
b. Resin development complexity: The formulation of new resins requires the more careful tuning of photoinitiators, monomers and oligomers to achieve stability and consistent performance41.
c. Cost and availability: The use of new SLA materials, especially biocompatible or high-temperature resins, can also come at high costs and be difficult to access42.
d. Toxicity: Several of the photopolymers entail toxicity hazards that are difficult to handle, stored and disposed43.
3. SLS- Selective Laser Sintering:
Selective Laser Sintering (SLS) A laser usually CO2 fuses polymer powder into 3D shapes. Computer-directed laser scans a pattern while powder in a chamber is heated to near its melting temperature; the particles are then sintered together to create solid sections as shown in Figure 344.
Figure 3: SLS- Selective Laser Sintering
Advantages:
a. Material efficiency and versatility: SLS enables parts to be built directly from digital files, realizing high efficient utilization of materials and design freedom45.
b. Better mechanical properties: SLS parts have better mechanical properties compared to other AM processes and need less usage of support structure46.
c. Material flexibility: SLS is capable of processing a wide range of materials (polymers, some metals, ceramics and composites) which has resulted in it being one of the fastest evolving AM processes47.
d. Solvent-free: No solvents are used in the process (unlike SLA or some 3DP methods, for example), meaning that solvent sensitive drug molecules can be printed48.
Disadvantages:
a. Deformation and warping: The most common problem with SLS is the deformation, shrinkage, and warping caused by fast cooling of the printed parts49.
b. Powder Handling and Reuse: Powders may tend to degrade with heating and from exposure to laser energy with each build cycle. Mechanical properties of the parts are influenced by aging, which can also result in a poor surface finish. Moreover, contamination of parts with foreign particles or degraded powder can affect quality and reproducibility50.
c. Surface: The SLS-manufactured parts can be grainy and additional post-processing (e.g. aeration or graining) might be needed to achieve the desired surface smoothness51.
d. Dimensional Accuracy: The sintering process is such that high precision of dimensions are difficult to obtain. Parameters such as laser focus and the powder layer can affect the final part size52.
4. DED: Direct energy Deposition:
The DED process, commonly known as 3D welding, builds near-net shape parts from a wire or powder using laser as an energy source53. It can make new metal parts nickel alloys, for example or repair damaged ones. As DED can manufacture metal parts by eliminating assembly components, its applications are broad including automotive (gear, knob, gear-boxes, and bumpers), medical (implants, scaffolds and earplugs) and aerospace (blades, engine components and brackets). Concentrated sources of thermal energy, such as lasers, plasma arcs and electron beams as shown in Figure 4 are capable of melting or welding materials. It is like let's take it layer by layer top to bottom. The main constituents of DED are repair of parts, producing complex metallic objects by printing, and cladding in coating54.
Figure 4: Direct energy deposition
Advantages:
a. Depending on the nature of three-dimensional surface: DED processes are capable of line-by-line build-up metallic material to form desired shape on regular and irregular surfaces.
b. Mixed materials: Using this, the DED systems can produce a mixed material with desired characteristics through multi-material and multi-pass deposition of different materials.
c. Hybrid manufacturing: Enabling a hybrid process between DED and other processing techniques happens to be more practical.
d. Repairs, Restorations and Remanufacturing: DED processes have several favorable characteristics including excellent mechanical properties with less warpage, lower heat input55.
Disadvantages:
a. Restricted sectional size: DED has generally a smaller build volume than other additive manufacturing techniques and, therefore, it is not possible to print large parts56.
b. Surface quality: The parts produced by DED usually have rough surface finish, hence requiring post-processing to achieve correct dimensions and desired smoothness57.
c. Material wastage: Materials wastage i.e., when printing complex geometries more waste is produced during the process than other AM techniques58.
d. Residual thermal stresses resulting from rapid cooling on the deposition process could affect mechanical properties and dimensional stability of the final constituted parts59.
e. Equipment cost: DED systems are expensive to purchase and maintain given their significant initial expenses and ongoing costs, which renders them more costly than several alternative AM technologies60.
Formulation and materials for 3D printed dysmenorrhea patch:
Table 1: Polymers and excipients:
|
Sr. No. |
Polymer/Excipient |
Role |
|
1. |
Polyvinyl alcohol (PVA) |
Soluble in water: control release, flexibility and adhesion61 |
|
2. |
Polyvinylpyrrolidone (PVP) |
Binder and film-former; beneficial in even dispersion and solubility62 |
|
3. |
Hydroxypropyl methylcellulose (HPMC) |
Aqueous matrix; controls patch integrity, mucoadhesion and release63 |
|
4. |
Polylactic acid |
Biodegradable structural polymer; biodegradable PLA; mechanical properties64 |
|
5. |
Polycaprolactone (PCL) |
Flexible biodegradable polymer; better penetration, tailored algorithm to degradation65 |
|
7. |
Poly (lactic-co-glycolic acid) (PLGA) |
Biodegradable copolymer in which degradation, encapsulation and sustained release can be tailored66 |
|
9. |
Eudragit polymers |
ph-responsive acrylic-based polymers possessing stability, solubility and targeted release67 |
|
10. |
Cyclodextrins (CDs) |
Oligosaccharide excipients: release, stability and solubility enhancement68 |
Table 2: Plasticizers and adhesives:
|
Sr. No. |
Plasticizer and Adhesives |
Role |
|
1. |
Polyethylene glycol (PEG) |
Role of plasticizer is increasing the flexibility, reducing the brittleness, enhancing adhesion and to increase solubility and release 69 |
|
2. |
Polyacrylates (e.g., polymethyl acrylate, poly (2-ethylhexyl acrylate)) |
Strong adhesion, sustained drug release, pressure-sensitive adhesive and modulable adhesion force |
|
3. |
Propylene glycol |
Modifies penetration and enhances flexibility and solubility. |
|
4. |
Triethyl citrate (TEC) |
Plasticizer, which promote plasticity and reduce Tg 70 |
|
5. |
Silicone adhesives |
Good compatibility, controlled-released, and mild adherent |
|
6. |
Acrylic copolymers adhesives |
Robust, water-resistant adherence 71 |
Table 3: Backing layer, Release liner and permeation enhancer:
|
Sr. No. |
Release liner, Backing layer and permeation enhancer |
Role |
|
1. |
Polyurethane film |
Flexibility, mechanical support, waterproof, evaporate barrier |
|
2. |
Silicone-coated polyester |
Stability, low pull force and adhesive protection before use 72 |
|
3. |
Polyester film |
Stability and life of patch backing |
|
4. |
Fluoropolymer-coated paper |
Protects the drug layer, prevents adhesion prior to placement, peels easily off. |
|
5. |
Propylene glycol |
Hydrating, soluble and enhances penetration 73 |
|
6. |
Dimethyl sulfoxide (DMSO) |
Potent penetration/permeation enhancer due to skin barrier disruption 74 |
|
7. |
Menthol |
Transforms lipid’s structure, promoting permeability 75 |
Characterization of 3D printed patches:
a) Physicochemical Characterization:
Thickness: The thickness of the patch was measured using a screw gauge micrometer (minimum count 0.01mm). Thickness uniformity was measured at three different points, and the standard deviation is an average of a triple reading.
Uniformity of weight: The 2x2 cm˛ patch was expected to be cut into sectors and weighed using a digital balance. The average and standard deviation values need to be computed for the individual weights76.
Folding endurance: The number of times, a specimen when cut at breaking point can be folded at the same place back and forth. The number of folded film could be folded in the same place without breaking was used to calculate folding endurance77.
Tensile strength: The films were evaluated by a texture analyzer (Instron Universal Model) equipped with a 500g load cell. A cm film strip (without any physical defects and air bubbles) between clamps of a 10*10mm was placed. The upper clamp drew the film-off at a rate of 10mm/min while measuring. Measurements of elongation and force were made at the time of fracture of the films. For each movie, the measurements were repeated four times. The tensile strength and elongation at break were calculated using the following equation:
The tensile strength (kg/mm2) was calculated as breaking force (kg) sample cross-sectional area (mm2).
The elongation at break (%) is defined as the increase in length at break (mm) divided by the initial length (mm) multiplied by 100%78.
b) Scanning electron microscopy:
Surface characteristics such as surface smoothness and diameter uniformity are important factors that influence the quality of the nanofiber sheet produced. The surface morphology and the fiber diameter of the optimized nanofibers were observed in an SEM (scanning electron microscope)79.
c) Drug content uniformity of films:
The 1cm2 patches were cut out and placed in a beaker containing 100mL of pH 7.4 phosphate buffer. Medium was stirred by a magnet bead. The filtrate was filtered on Whatmann filter paper and the drug content in the filtrate was determined by spectrophotometry at 322nm as compared to a reference solution prepared from placebo films that do not contain any drug. To reproduce the result, the experiment was repeated80.
d) In vitro drug release studies:
Franz diffusion cell: The device consists of donor and receptor compartments. The receiver compartment with an effective area of 1–5 cm˛ and volume of 5–12mL. The diffusion buffer is stirred by a magnetic bar at a constant 600 rpm. The solution temperature is kept by circulating water in a water jacket around the receptor chamber.
(USP Apparatus 7) Reciprocating disc: In this method, a membrane patches to holders in a small volume solution, and the device has the capability of delivering drug at low concentration. Then the paddle over extraction cell technique is used.
Flow through diffusion cell: Flow through diffusion cells can be used when the drug is less soluble in the receptor compartment. This cell can be directly linked to an HPLC and has its operation fully automated. A small volume (0.3mL) receiver chamber is also used to allow for rapid removal of penetrating agent at relatively low pumping rates, with the use of a large capacity donor chamber to facilitate loading of compound applied81.
e) Ex vivo skin permeation studies:
The formulation was further optimized by ex vivo permeation study using goat abdomen skin membrane in a 250 ml receptor compartment of Franz diffusion cell to achieve the best performance. The goat's abdominal membrane was obtained from a slaughterhouse, washed twice with distilled water and placed between the receptor compartment and donor of the diffusion cell. The prepared patch (2 × 1cm2) was trimmed to cover the membrane of goat abdominal skin, and phosphate buffer pH 7.4 was added to the receptor compartment of diffusion cell. The whole assembly was mounted on a magnetic stirrer and the solution in the receptor compartment was stirred continuously under magnetic little beads at 100rpm using magnetic bead stirring system; A temperature of 37±0.50°C as built into diffusion cell throughout experiment. 5ml aliquots were withdrawn at intervals of 1, 3, 6, 9-18hours and its drug content was determined spectrophotometrically at the wavelength of 310nm with a blank. A same volume of phosphate buffer (pH 7.4) was replaced at each sample withdrawal instead the receptor medium. Graphs of the cumulative mount of drug released versus time were constructed82.
f) Stability studies:
Based on ICH guidelines, stability studies were conducted by storing the TTDS samples for a period of 6 months at 40±0.5°C and humidity conditions to be maintained at 75±5%. Withdrawal the samples at 0, 30, 60, 90 and 180 days and tested for their drug content in detail83.
Benefits of the 3d printed custom patch:
1. 3D printing enables the creation of patient-specific and personalized items that are designed to match individual patients’ needs in order to enhance treatment efficiency and safety84.
2. Additive manufacturing enables the formation of complex shapes and architectures which are hard to be produced by conventional approaches85.
3. Customizing patches to each patient in this manner may improve patient adherence and efficacy of treatment with the ability to tailor dosing, release profiles, and the geometry of the patch.
4. Rapid prototyping of 3D printing patches and real personalized patches for better therapeutic efficacy86.
Uses of 3D Printed personalized patch:
1. 3D printed microneedle patches addressing the global challenges of vaccination, with pain-free skin delivery and improved immunogenicity.
2. Therapeutic effectiveness is optimized and side effects are minimized with 3D printing technology, producing individualized drug dosage forms specifically tailored to the patient87.
3. Compared to the conventional injection approach, the 3D-printed microneedles provide a new painless and low invasive method for transdermal drug delivery with improved patient compliance.
4. 3D printing support for compartment patches (releasing with different kinetics) and personalized dose shapes, and formulation of more than one active ingredients in a single patch88.
Advantages of 3d printing transdermal patch for dysmenorrhea compared with the traditional patch:
1. Heat Therapy patches: "This 3D printed patch could make practicing heat therapy at home more convenient for patients with dysmenorrhea." Possibly it has more precise and consistent heat delivery, the possibility of variations in designs for better fit and comfort, and the option of controlled drug release. This might avoid the variability of modalities and duration on heat application observed in earlier studies. Yet issues of small sample sizes, possible biases, and the lack of long-term safety data would still have to be addressed by robust clinical trials. The superiority of the patch in minimizing side effects, as compared to standard treatments, would need to be carefully assessed. In conclusion, though this 3D printed patch is very encouraging it would demand rigorous scientific application to prove that the novelty of 3D printing the patch outmatches other available options89.
2. Herbal and cooling patches: A few studies suggest that herbal and cooling patches are not very effective in the treatment of dysmenorrhea such as slight reduction of pain for a couple of hours. They also can lead to skin irritation and have variable drug release. 3D-printed transdermal patches, on the other hand, address these drawbacks with better penetration of drugs into the skin, controlled sustained release of drug, minimized irritation as well as modifiable dosing. These patches allow specific drugs, such as analgesics or NSAIDs to be transferred directly through the skin at accurate doses. They provide enhanced effectiveness, durable treatment-effect duration and may be used in combination.
3. Oral tablets and capsules: Oral tablets and capsules its disadvantages include the gastrointestinal adverse effects, slow acting nature, systemic side effects such as first-pass metabolism and irregular absorption. By bypassing the GI tract, giving rapid onset of action, reducing systemic exposure, and avoiding first-pass metabolism and maintaining a controlled drug release, 3D-printed transdermal patches address these issues. These patches may be customized to the needs of each patient leading to increased patient comfort and overall therapeutic effectiveness. 3D-printed transdermal patches can be an alternative healthcare solution to conventional oral forms of medications, as they offer an opportunity for controlled drug delivery with accurately tailored dosage and release-kinesis90.
4. Topical gels and creams: Local gels and creams have a number of drawbacks: poor absorption through the skin, short half-life, variable dosing and risk of skin irritation. These drawbacks could reduce their effectiveness and patient adherence. 3D-printed transdermal patches, in contrast, offer a solution to these issues. They enhance drug penetration using microneedle arrays or permeation enhancers; offer sustained release for prolonged effects; unvarying dosing with precise amounts of drugs; and reduced risk of skin irritation by controlled delivery as well as enhanced comfort and convenience. These new patches represent a significant development in the field of dermal drug delivery and have the potential to improve patient outcomes by overcoming some limitations associated with traditional formulations91.
Challenges and limitations:
However, the application of 3D printing technology for transdermal drug delivery systems still lies with some challenges and limitations:
Pricey 3D printers, and special excipients: The expensive price tag of advanced 3D printers needed for pharmaceutical grade transdermal patch has dissuaded a lot of other industrial and research institutions to utilize them. Additionally, the drug- and biocompatible materials required to 3D print such patches can be costly, and they may not be readily available.
Uncertainties in regulations: Regulations about transdermal patches and some of the other 3D printing products are still in flux. 3D-printed transdermal patches may be further delayed and manufacturers could possibly face uncertainty of regulation pathways.
Issues with reproducibility and scale-up: Customization and low volume production are advantages of 3D printing, however there is disadvantage when it comes to scaling up for manufacturing in larger commercial quantities. Manufacturers must develop sound quality control methods and demonstrate batch-to-batch consistency to comply with regulatory requirements.
Patient awareness and acceptability: Patients themselves are still getting used to the idea of 3D-printed drugs like transdermal patches. In order to be well-received and effectively utilized, patients and healthcare professionals require education about their benefits and appropriate use of 3D-printed transdermal patches.
Variability in transdermal absorption and skin irritation: Some patients may develop allergies or irritations due to transdermal delivery systems, such as 3D-printed patches. To address these challenges, scientists have to develop biocompatible materials and further optimize the patch design to avoid skin irritation and ensure consistent drug absorption across all patient types.
More research to tackle these challenges, both watching collaboration between industry and academia work in progress in consulting agencies to generate uniform rules for the development and retailing of 3D-printed TDDS.
Future prospectives:
· Coupling advanced biosensors with transdermal patches will enable incessant surveillance of the physiological responses, body temperature, and pain levels which in turn would provide an opportunity for real time dosage adjustments.
· By taking into account patient-specific data by employing AI-based systems, an optimal dosage and release rate of the drug can be determined that might pave the way for fully individualized therapy.
· As 3D bioprinting provides a high level of control over patch architecture, material composition and drug release kinetics, the technique is expected to be most effective in the context of spatially targeted hormone therapy such as endometriosis.
· 4D printing, with the aid of responsive and adaptive materials, can enable smart patches that can dynamically respond to changes in the environment or body for more effective treatment.
· It is imperative to adhere on preclinical and clinical studies in order to establish the safety, stability, and treatment efficacy of these new transdermal systems to ensure their clinical reliability.
· Drivers for oncology applications While the manufacturing of this class of EVs is possible at industrial level, several key issues will need to be addressed before broad commercialization: regulatory approval steps, scalability of production, and cost competitiveness.
CONCLUSION:
Summary of the main results is presented in the conclusion and shows the prospect for personalized 3D-printed patches that enable effective dysmenorrhea intervention. It highlights the importance of regulatory guidance and translational research to facilitate translation of this promising finding. The next generation of smart patches for transdermal drug delivery may include sensors and real-time monitoring of pain or temperature to adjust treatments based on data. By predicting the optimal doses using patient data, A.I. could enhance personalization. The 3-dimensional structure and composition of patches is particularly promising in the case of hormone delivery for diseases like endometriosis. In 4D printing – an emerging technology that develops 3D-printed objects using stimuli-responsive materials – this could lead to patches which change according to the body's you can program. In summary, 3D-printed individualized patches could plays a crucial role in the treatment of dysmenorrhea, and this is just one aspect of their potential use. Converting these breakthroughs into revolutionary changes in patient care and health care delivery will require sustained investment in research, development, and regulation.
LIST OF SYMBOLS:
|
% |
Percent |
|
+ |
Plus |
|
– |
Dash or minus |
|
° |
Degree |
|
× |
Multiplication |
|
Μ |
Micrometers |
|
± |
Plus-minus, for error margins or variability |
|
°C |
Degree Celsius, |
|
÷ |
Division |
List of Abbreviations:
|
AM: |
Additive Manufacturing |
|
AI: |
Artificial Intelligence |
|
3D: |
Three-dimensional |
|
4D: |
Four-dimensional |
|
CAD: |
Computer-Aided Design |
|
DED: |
Direct Energy Deposition |
|
FDM: |
Fused Deposition Modeling |
|
FFF: |
Fused Filament Fabrication |
|
GnRH: |
Gonadotropin-Releasing Hormone |
|
HPMC: |
Hydroxypropyl Methylcellulose |
|
NSAIDs: |
Nonsteroidal anti-inflammatory drugs |
|
PLGA: |
Poly (lactic-co-glycolic acid) |
|
PVP: |
Polyvinylpyrrolidone |
|
SEM: |
Scanning Electron Microscope |
|
SLA: |
Stereolithography |
|
SLS: |
Selective Laser Sintering |
|
PVA: |
Polyvinyl alcohol |
|
PCL: |
Polycaprolactone |
|
CDs: |
Cyclodextrins |
|
PEG: |
Polyethylene glycol |
|
TEC: |
Triethyl citrate |
|
DMSO: |
Dimethyl sulfoxide |
REFERENCES:
1. Kirsch E, Rahman S, Kerolus K, Hasan R, Kowalska DB, Desai A, Bergese SD. Dysmenorrhea, a narrative review of therapeutic options. Journal of Pain Research. 2024 Dec 31: 2657-66. https://doi.org/10.2147/JPR.S459584
2. Wang L, Yan Y, Qiu H, Xu D, Zhu J, Liu J, Li H. Prevalence and risk factors of primary dysmenorrhea in students: a meta-analysis. Value in Health. 2022; 25(10): 1678-84. https://doi.org/10.1016/j.jval.2022.03.023
3. Martire FG, Piccione E, Exacoustos C, Zupi E. Endometriosis and adolescence: the impact of dysmenorrhea. Journal of clinical medicine. 2023; 12(17): 5624. https://doi.org/10.3390/jcm12175624
4. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Human reproduction update. 2015; 21(6): 762-78. https://doi.org/10.1093/humupd/dmv039
5. Hong F, He G, Zhang M, Yu B, Chai C. The establishment of a mouse model of recurrent primary dysmenorrhea. International Journal of Molecular Sciences. 2022; 23(11): 6128. https://doi.org/10.3390/ijms23116128
6. Torkan B, Mousavi M, Dehghani S, Hajipour L, Sadeghi N, Ziaei Rad M, Montazeri A. The role of water intake in the severity of pain and menstrual distress among females suffering from primary dysmenorrhea: a semi-experimental study. BMC Women's Health. 2021; 21(1): 40.
7. Itani R, Soubra L, Karout S, Rahme D, Karout L, Khojah HM. Primary dysmenorrhea: pathophysiology, diagnosis, and treatment updates. Korean Journal of Family Medicine. 2022; 43(2): 101. https://doi.org/10.4082/kjfm.21.0103
8. Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. Bmj. 2006; 332(7550): 1134-8. https://doi.org/10.1136/ bmj.332.7550.1134
9. Krzemińska P, Kołodziej J, Biniewicz A. Primary and secondary dysmenorrhea: symptoms, risk factors, diagnosis, and treatment–review. Quality in Sport. 2024; 21: 53346-. https://doi.org/10.12775/QS.2024.21.53346
10. Brown J, Crawford TJ, Allen C, Hopewell S, Prentice A. Nonsteroidal anti‐inflammatory drugs for pain in women with endometriosis. Cochrane Database of Systematic Reviews. 2017(1). https://doi.org/10.1002/14651858.CD004753.pub4
11. Alonso A, Gunther K, Maheux-Lacroix S, Abbott J. Medical management of endometriosis. Current Opinion in Obstetrics and Gynecology. 2024; 36(5): 353-61. DOI: 10.1097/GCO.000000000000098
12. McKernan LC, Crofford LJ, Kim A, Vandekar SN, Reynolds WS, Hansen KA, Clauw DJ, Williams DA. Electronic delivery of pain education for chronic overlapping pain conditions: a prospective cohort study. Pain Medicine. 2021; 22(10): 2252-62. https://doi.org/ 10.1093/pm/pnab018
13. Dick A, Matok I, Gutman-Ido E, Lessans N, Dior UP. GnRH analogues and dienogest for second line treatment of endometriosis-associated pain: a systematic review, meta-analysis, and network meta-analysis. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2025 Jun 10:114093. https://doi.org/10.1016/j.ejogrb.2025.114093
14. Csirzó Á, Kovács DP, Szabó A, Szabó B, Jankó Á, Hegyi P, Nyirády P, Ács N, Valent S. Comparative analysis of medical interventions to alleviate endometriosis-related pain: a systematic review and network meta-analysis. Journal of Clinical Medicine. 2024; 13(22): 6932. https://doi.org/10.3390/jcm13226932
15. Giese N, Kwon KK, Armour M. Acupuncture for endometriosis: a systematic review and meta-analysis. Integrative Medicine Research. 2023; 12(4): 101003. https://doi.org/10.1016/j.imr.2023.101003
16. Chen C, Li X, Lu S, Yang J, Liu Y. Acupuncture for clinical improvement of endometriosis-related pain: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics. 2024; 310(4): 2101-14. https://doi.org/10.1007/s00404-024-07675-z
17. Li L, Lou K, Chu A, O’Brien E, Molina A, Riley K. Complementary therapy for endometriosis related pelvic pain. Journal of Endometriosis and Pelvic Pain Disorders. 2023; 15(1): 34-43. https://doi.org/10.1177/22840265231159704
18. Tennfjord MK, Gabrielsen R, Tellum T. Effect of physical activity and exercise on endometriosis-associated symptoms: a systematic review. BMC Women's Health. 2021; 21(1): 355. https://doi.org/10.1186/s12905-021-01500-4
19. Mikocka-Walus A, Druitt M, Melissa O, Skvarc D, Watts JJ, Esterman A, Tsaltas J, Knowles S, Harris J, Dowding C, Parigi E. Yoga, cognitive–behavioural therapy versus education to improve quality of life and reduce healthcare costs in people with endometriosis: a randomised controlled trial. BMJ Open. 2021; 11(8): e046603. https://doi.org/10.1136/bmjopen-2020-046603
20. Armour M, Sinclair J, Chalmers KJ, Smith CA. Self-management strategies amongst Australian women with endometriosis: a national online survey. BMC complementary and alternative medicine. 2019; 19(1): 17. https://doi.org/10.1186/s12906-019-2431-x
21. Prashar G, Vasudev H, Bhuddhi D. Additive manufacturing: expanding 3D printing horizon in industry 4.0. International Journal on Interactive Design and Manufacturing (IJIDeM). 2023; 17(5): 2221-35. https://doi.org/10.1007/s12008-022-00956-4
22. Zhou L, Miller J, Vezza J, Mayster M, Raffay M, Justice Q, Al Tamimi Z, Hansotte G, Sunkara LD, Bernat J. Additive manufacturing: a comprehensive review. Sensors. 2024; 24(9): 2668. https://doi.org/10.3390/s24092668
23. Tofail SA, Koumoulos EP, Bandyopadhyay A, Bose S, O’Donoghue L, Charitidis C. Additive manufacturing: scientific and technological challenges, market uptake and opportunities. Materials Today. 2018; 21(1): 22-37. https://doi.org/10.1016/j.mattod.2017.07.001
24. Singh S, Urooj S, Batra N, Kalathil S. Healthcare applications of 3D printing in human implants: a review. In2020 IEEE 17th India Council International Conference (INDICON) 2020 Dec 10 (pp. 1-6). IEEE. https://doi.org/10.1109/INDICON49873.2020.9342316
25. Thakar CM, Parkhe SS, Jain A, Phasinam K, Murugesan G, Ventayen RJ. 3d Printing: Basic principles and applications. Materials Today: Proceedings. 2022 Jan 1; 51: 842-9. https://doi.org/10.1016/j.matpr.2021.06.272
26. Praveena BA, Lokesh N, Santhosh N, Praveena BL, Vignesh R. A comprehensive review of emerging additive manufacturing (3D printing technology): Methods, materials, applications, challenges, trends and future potential. Materials Today: Proceedings. 2022 Jan 1; 52: 1309-13. https://doi.org/10.1016/j.matpr.2021.11.059
27. Prabhakar MM, Saravanan AK, Lenin AH, Mayandi K, Ramalingam PS. A short review on 3D printing methods, process parameters and materials. Materials Today: Proceedings. 2021 Jan 1; 45: 6108-14. https://doi.org/10.1016/j.matpr.2020.10.225
28. Truby RL, Lewis JA. Printing soft matter in three dimensions. Nature. 2016 Dec 15;540(7633):371-8. https://doi.org/10.1038/nature21003
29. Zhan S, Guo AX, Cao SC, Liu N. 3D printing soft matters and applications: a review. International Journal of Molecular Sciences. 2022; 23(7): 3790. https://doi.org/10.3390/ijms23073790
30. Simon MC, Laios K, Nikolakakis I, Papaioannou TG. Three-Dimensional printing technology in drug design and development: Feasibility, challenges, and potential applications. Journal of Personalized Medicine. 2024 Oct 29;14(11):1080. https://doi.org/10.3390/jpm14111080
31. Goyanes A, Chang H, Sedough D, Hatton GB, Wang J, Buanz A, Gaisford S, Basit AW. Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing. International Journal of Pharmaceutics. 2015; 496(2): 414-20. https://doi.org/10.1016/j.ijpharm.2015.10.039
32. Polabutta, K.; Sangnim, T. Design and development of zero-order drug release gastroretentive floating tablets fabricated by 3D printing technology. J. Drug Deliv. Sci. Technol. 2019; 52: 831–837 https://doi.org/10.1016/j.jddst.2019.06.004
33. Auel T, Mentrup AF, Oldfield LR, Seidlitz A. 3D printing of pharmaceutical dosage forms: Recent advances and applications. Advanced Drug Delivery Reviews. 2025 Feb 1; 217: 115504. https://doi.org/10.1016/j.addr.2024.115504
34. Salama AH. Recent advances in 3D and 4D printing in pharmaceutical technology: applications, challenges, and future perspectives. Future Journal of Pharmaceutical Sciences. 2025 Aug 13; 11(1): 107. https://doi.org/10.1186/s43094-025-00866-8
35. Johannesson J, Wu M, Johansson M, Bergström CA. Quality attributes for printable emulsion gels and 3D-printed tablets: Towards production of personalized dosage forms. International Journal of Pharmaceutics. 2023 Nov 5; 646: 123413. https://doi.org/ 10.1016/j.ijpharm.2023.123413
36. Blaj M, Oancea G. Fused deposition modelling process: a literature review. In IOP Conference Series: Materials Science and Engineering 2021; 1009(1); 12006. doi:10.1088/1757-899X/1009/1/012006
37. Rajan K, Samykano M, Kadirgama K, Harun WS, Rahman MM. Fused deposition modeling: process, materials, parameters, properties, and applications. The International Journal of Advanced Manufacturing Technology. 2022; 120(3): 1531-70. https://doi.org/10.1007/s00170-022-08860-7
38. Husna A, Ashrafi S, Tomal AA, Tuli NT, Rashid AB. Recent advancements in stereolithography (SLA) and their optimization of process parameters for sustainable manufacturing. Hybrid Advances. 2024 Dec 1; 7: 100307. https://doi.org/10.1016/j.hybadv.2024.100307
39. Arcaute K, Mann BK, Wicker RB. Stereolithography of three-dimensional bioactive poly (ethylene glycol) constructs with encapsulated cells. Annals of Biomedical Engineering. 2006; 34(9): 1429-41. https://doi.org/10.1007/s10439-006-9156-y
40. Pagac M, Hajnys J, Ma QP, Jancar L, Jansa J, Stefek P, Mesicek J. A review of vat photopolymerization technology: materials, applications, challenges, and future trends of 3D printing. Polymers. 2021; 13(4): 598. https://doi.org/10.3390/polym13040598
41. Huang J, Qin Q, Wang J. A review of stereolithography: Processes and systems. Processes. 2020; 8(9): 1138. https://doi.org/10.3390/ pr8091138
42. Ngo TD, Kashani A, Imbalzano G, Nguyen KT, Hui D. Additive manufacturing (3D printing): A review of materials, methods, applications and challenges. Composites Part B: Engineering. 2018; 143: 172-96. https://doi.org/10.1016/j.compositesb.2018.02.012
43. Stansbury JW, Idacavage MJ. 3D printing with polymers: Challenges among expanding options and opportunities. Dental Materials. 2016; 32(1): 54-64. https://doi.org/10.1016/j.dental.2015.09.018
44. Jadhav A, Jadhav VS. A review on 3D printing: An additive manufacturing technology. Materials Today: Proceedings. 2022; 62: 2094-9. https://doi.org/10.1016/j.matpr.2022.02.558
45. Zhang S, Tang H, Tang D, Liu T, Liao W. Effect of fabrication process on the microstructure and mechanical performance of carbon fiber reinforced PEEK composites via selective laser sintering. Composites Science and Technology. 2024; 246: 110396. https://doi.org/10.1016/ j.compscitech.2023.110396
46. Han W, Kong L, Xu M. Advances in selective laser sintering of polymers. International Journal of Extreme Manufacturing. 2022; 4(4): 042002. https://doi.org/10.1088/2631-7990/ac9096
47. Kruth JP, Wang X, Laoui T, Froyen L. Lasers and materials in selective laser sintering. Assembly Automation. 2003; 23(4): 357-71. https://doi.org/10.1108/01445150310698652
48. Kruth JP. Material increase manufacturing by rapid prototyping techniques. CIRP Annals. 1991 Jan 1; 40(2): 603-14. https://doi.org/10.1016/S0007-8506(07)61136-6
49. Kruth JP, Levy G, Klocke F, Childs TH. Consolidation phenomena in laser and powder-bed based layered manufacturing. CIRP Annals. 2007 Jan 1;56(2):730-59. https://doi.org/10.1016/j.cirp.2007.10.004
50. Yehia HM, Hamada A, Sebaey TA, Abd-Elaziem W. Selective laser sintering of polymers: process parameters, machine learning approaches, and future directions. Journal of Manufacturing and Materials Processing. 2024; 8(5): 197. https://doi.org/10.3390/ jmmp8050197
51. Rouway M, Nachtane M, Tarfaoui M, Chakhchaoui N, Omari LE, Fraija F, Cherkaoui O. 3D printing: Rapid manufacturing of a new small-scale tidal turbine blade. The International Journal of Advanced Manufacturing Technology. 2021; 115(1): 61-76. https://doi.org/10.1007/ s00170-021-07163-7
52. Hao M, Wang J, Wang R, Gong M, Zhang L, Wang D, Lu Y, Zhang L, Lin X. Mechanical dependence of 3D-printed thermoplastic polyurethane reinforced with minor continuous carbon fibres. Virtual and Physical Prototyping. 2023; 18(1): e2224304. https://doi.org/10.1080/17452759.2023.2224304
53. P. Bajaj, A. Hariharan, A. Kini, P. Kürnsteiner, D. Raabe, E.A. J€agle, Steels in additive manufacturing: A review of their microstructure and properties, Mater. Sci. Eng. A. 772 (2020) 138633. https://doi.org/10.1016/j.msea.2019.138633.
54. Dezaki ML, Serjouei A, Zolfagharian A, Fotouhi M, Moradi M, Ariffin MK, Bodaghi M. A review on additive/subtractive hybrid manufacturing of directed energy deposition (DED) process. Advanced powder materials. 2022; 1(4): 100054. https://doi.org/10.1016/j.apmate.2022.100054
55. Ahn DG. Directed energy deposition (DED) process: state of the art. International Journal of Precision Engineering and Manufacturing-Green Technology. 2021; 8(2): 703-42. https://doi.org/10.1007/s40684-020-00302-7
56. Özel T, Shokri H, Loizeau R. A review on wire-fed directed energy deposition-based metal additive manufacturing. Journal of Manufacturing and Materials Processing. 2023; 7(1): 45. https://doi.org/10.3390/jmmp7010045
57. Piscopo G, Salmi A, Atzeni E. Investigation of dimensional and geometrical tolerances of laser powder directed energy deposition process. Precision Engineering. 2024; 85: 217-25. https://doi.org/10.1016/j.precisioneng.2023.10.006
58. Ramos A, Angel VG, Siqueiros M, Sahagun T, Gonzalez L, Ballesteros R. Reviewing Additive Manufacturing Techniques: Material Trends and Weight Optimization Possibilities Through Innovative Printing Patterns. Materials. 2025; 18(6): 1377. https://doi.org/10.3390/ ma18061377
59. Tariq U, Wu SH, Mahmood MA, Woodworth MM, Liou F. Effect of pre-heating on residual stresses and deformation in laser-based directed energy deposition repair: A comparative analysis. Materials. 2024; 17(10): 2179. https://doi.org/10.3390/ma17102179
60. Farias FW, dos Santos TJ, Oliveira JP. Directed energy deposition+ mechanical interlayer deformation additive manufacturing: a state-of-the-art literature review. The International Journal of Advanced Manufacturing Technology. 2024; 131(3): 999-1038. https://doi.org/10.1007/s00170-024-13126-5
61. Couți N, Porfire A, Iovanov R, Crișan AG, Iurian S, Casian T, Tomuță I. Polyvinyl Alcohol, a versatile excipient for pharmaceutical 3D printing. Polymers. 2024; 16(4): 517. https://doi.org/10.3390/polym16040517
62. Lopez-Vidal L, Juskaite K, Fandino O, Fuster MG, Sangalli M, Adhami M, Wang J, Palma SD, Volpe-Zanutto F, Larraneta E, Paredes AJ. 3D-printed acyclovir nanocrystals: An advanced approach to herpes simplex treatment. Applied Materials Today. 2025; 44: 102695. https://doi.org/10.1016/j.apmt.2025.102695
63. Chanabodeechalermrung B, Chaiwarit T, Chaichit S, Udomsom S, Baipaywad P, Worajittiphon P, Jantrawut P. HPMC/PVP K90 dissolving microneedles fabricated from 3D-printed master molds: Impact on microneedle morphology, mechanical strength, and topical dissolving property. Polymers. 2024; 16(4): 452. https://doi.org/10.3390/polym16040452
64. Cardoso PH, Araújo ES. An approach to 3D printing techniques, polymer materials, and their applications in the production of drug delivery systems. Compounds. 2024; 4(1): 71-105. https://doi.org/10.3390/compounds4010004
65. de Oliveira RS, Fantaus SS, Guillot AJ, Melero A, Beck RC. 3D-printed products for topical skin applications: from personalized dressings to drug delivery. Pharmaceutics. 2021; 13(11): 1946. https://doi.org/10.3390/pharmaceutics13111946
66. Yang J, Zeng H, Luo Y, Chen Y, Wang M, Wu C, Hu P. Recent applications of PLGA in drug delivery systems. Polymers. 2024; 16(18): 2606. https://doi.org/10.3390/polym16182606
67. Dos Santos J, da Silva GS, Velho MC, Beck RC. Eudragit®: A versatile family of polymers for hot melt extrusion and 3D printing processes in pharmaceutics. Pharmaceutics. 2021; 13(9): 1424. https://doi.org/10.3390/pharmaceutics13091424
68. Alvarez-Lorenzo C, Goyanes A, Concheiro A. Cyclodextrins in 3D/4D printing for biomedical applications. Additive Manufacturing. 2024; 84: 104120. https://doi.org/10.1016/j.addma.2024.104120
69. Chan YL, Widodo RT, Ming LC, Khan A, Abbas SA, Ping NY, Sofian ZM, Kanakal MM. Review on 3D Printing Filaments Used in Fused Deposition Modeling Method for Dermatological Preparations. Molecules. 2025; 30(11): 2411. https://doi.org/10.3390/molecules30112411
70. Maciejewski B, Dłabiszewska J, Mikolaszek B, Sznitowska M. The Impact of Liquid Components on Alteration of the Adhesion of Polyacrylate and Silicone Patches. Polymers. 2023; 15(22): 4355. https://doi.org/10.3390/polym15224355
71. Fitzgerald DM, Colson YL, Grinstaff MW. Synthetic pressure sensitive adhesives for biomedical applications. Progress in polymer science. 2023; 142: 101692. https://doi.org/10.1016/j.progpolymsci.2023.101692
72. Chung EP, Nguyen JQ, Tellkamp-Schehr T, Goebel K, Ollek A, Krein C, Wells AR, Sebastian EA, Goebel A, Niese S, Leung KP. A Soft Skin Adhesive (SSA) Patch for Extended Release of Pirfenidone in Burn Wounds. Pharmaceutics. 2023; 15(7): 1842. https://doi.org/10.3390/pharmaceutics15071842
73. Mistry J, Notman R. Mechanisms of the drug penetration enhancer propylene glycol interacting with skin lipid membranes. The Journal of Physical Chemistry B. 2024; 128(16): 3885-97. https://doi.org/10.1021/acs.jpcb.3c06784
74. Otterbach A, Lamprecht A. Enhanced skin permeation of estradiol by dimethyl sulfoxide containing transdermal patches. Pharmaceutics. 2021; 13(3): 320. https://doi.org/10.3390/pharmaceutics13030320
75. Adamiak-Giera U, Gackowski M, Szostak J, Osmałek T, Malinowski D, Nowak A, Machoy-Mokrzyńska A, Miernik M, Halczak M, Romanowski M, Czerkawska A. Evaluation of the In Vitro Permeation Parameters of Topical Diclofenac Sodium from Transdermal Pentravan® Products and Hydrogel Celugel Through Human Skin. Pharmaceuticals. 2025; 18(6): 810. https://doi.org/10.3390/ph18060810
76. Hiroji MB, Nagesh C, Jani D, Chandrashekhara S. Development and Evaluation of Transdermal Drug Delivery System using Natural Polysaccharides. Research Journal of Pharmaceutical Dosage Forms and Technology. 2012;4(5):278-84. DOI: 10.5958/0975-4377
77. Nikitha MS, Veena M, Sneha M, Sreeya MS, Prerana MD, Sunitha D, Sudhakar M. Advancements in Transdermal Drug Delivery System. Asian J Pharm Technol. 2025; 15(3): 312-320. doi:10.52711/2231-5713.2025.00047.
78. Latha AV, Ravikiran TN, Kumar JN. Formulation, optimization, and evaluation of glibenclamide transdermal patches by using chitosan polymer. Asian Journal of Pharmacy and Technology. 2019; 9(1): 1-7. https://doi.org/10.5958/2231-5713.2019.00001.1
79. Choudhary S, Dharashivkar S, Mahajan C, Gaikwad M. Formulation and Evaluation of Nano-fiber-based Transdermal patch of Cephalexin. Research Journal of Pharmacy and Technology. 2020; 13(6): 2787-91. https://doi.org/10.5958/0974-360X.2020.00495.3
80. Hussain I, Narayanaswamy VB, Haque I, Hoque M. Design and evaluation of transdermal patches containing risperidone. Asian Journal of Research in Pharmaceutical Science. 2016; 6(4): 208-22. https://doi.org/10.5958/2231-5659.2016.00030.8
81. Panval AV, Chaudhari BP, Velhal AB, Redasani VK. A Novel Tool for Controlled Delivery: Transdermal Drug Delivery System. https://doi.org/10.52711/2231-5659.2022.00052
82. Reddy DP, Bhanja SB, Chauhan AK, Kumar BK, Panda DS, Panigrahi BB. Methanolic extraction, formulation, and evaluation of herbal transdermal patches of Azadirachta indica A. Juss. Research Journal of Pharmacy and Technology. 2021; 14(7): 3709-15. https://doi.org/10.52711/0974-360X.2021.00642
83. Lakshmi SS, Rao YS, Asha D, Kumari PK, Mallikarjun PN. Formulation and evaluation of rosuvastatin-calcium drug transdermal patch. Research Journal of Pharmacy and Technology. 2020; 13(10): 4784-90. https://doi.org/10.5958/0974-360X.2020.00841.0
84. Razzaghi M, Alexander Ninan J, Akbari M. Advancements in materials for 3D-printed microneedle arrays: Enhancing performance and biocompatibility. Micromachines. 2024; 15(12): 1433. https://doi.org/10.3390/mi15121433
85. Bhuskute H, Shende P, Prabhakar B. 3D printed personalized medicine for cancer: applications for betterment of diagnosis, prognosis, and treatment. AAPS PharmSciTech. 2021; 23(1): 8. https://doi.org/10.1208/s12249-021-02153-0
86. Mdanda S, Ubanako P, Kondiah PP, Kumar P, Choonara YE. Recent advances in microneedle platforms for transdermal drug delivery technologies. Polymers. 2021; 13(15): 2405. https://doi.org/10.3390/polym13152405
87. Simon MC, Laios K, Nikolakakis I, Papaioannou TG. Three-Dimensional printing technology in drug design and development: Feasibility, challenges, and potential applications. Journal of Personalized Medicine. 2024; 14(11): 1080. https://doi.org/10.3390/jpm14111080
88. Goyanes A, Chang H, Sedough D, Hatton GB, Wang J, Buanz A, Gaisford S, Basit AW. Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing. International Journal of Pharmaceutics. 2015; 496(2): 414-20. https://doi.org/10.1016/j.ijpharm.2015.10.039
89. Jo J, Lee SH. Heat therapy for primary dysmenorrhea: A systematic review and meta-analysis of its effects on pain relief and quality of life. Scientific Reports. 2018; 8(1): 16252. https://doi.org/10.1038/s41598-018-34303-z
90. Wong WF, Ang KP, Sethi G, Looi CY. Recent advancement of medical patch for transdermal drug delivery. Medicina. 2023; 59(4): 778. https://doi.org/10.3390/medicina59040778
91. Benson HA, Grice JE, Mohammed Y, Namjoshi S, Roberts MS. Topical and transdermal drug delivery: from simple potions to smart technologies. Current Drug Delivery. 2019; 16(5): 444-60. http://dx.doi.org/10.2174/1567201816666190201143457
|
Received on 10.10.2025 Revised on 22.12.2025 Accepted on 12.02.2026 Published on 14.07.2026 Available online from July 25, 2026 Research J. Science and Tech. 2026; 18(3):305-318. DOI: 10.52711/2349-2988.2026.00043
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|